Abstract #2247
Dual-modality evaluation of tumour vasculature, morphology and metabolism via Dynamic Susceptibility Contrast MRI and FluoroEthyl Choline-PET using simultaneous PET/MR
Maria Liljeroth 1 , Kjell Erlandsson 2 , Francesco Fraioli 2 , David Thomas 3 , Enrico De Vita 4 , Brian Hutton 2 , Anna Barnes 5 , Simon Arridge 6 , Sebastien Ourselin 7 , and David Atkinson 8
1
Institute of Nuclear Medicine, Metabolism &
Experimental Therapeutics, London, London, United
Kingdom,
2
Institute
of Nuclear Medicine, Metabolism & Experimental
Therapeutics, London, United Kingdom,
3
Institute
of Neurology, Faculty of Brain Sciences, Brain Repair &
Rehabilitation, London, United Kingdom,
4
National
Hospital for Neurology and Neurosurgery, Lysholm
Department of Neuroradiology, London, United Kingdom,
5
Institute
of Nuclear Medicine, Clinical Physics, London, United
Kingdom,
6
Faculty of Engineering Science, Dept
of Computer Science, London, United Kingdom,
7
Dept
of Med Phys & Biomedical Eng, London, United Kingdom,
8
Faculty
of Medical Sciences, Div of Medicine, London, United
Kingdom
Simultaneous 18FFECho PET and Dynamic Susceptibility
Contrast (DSC)/ Dynamic Contrast Enhanced (DCE) MRI has
the potential for providing valuable information
regarding tumour morphology and aggressiveness,
essential for tumour staging. We present data from a
conventional EPI perfusion acquisition strategy as well
as a dual-echo GRE approach which allows separation of
T1 and T2* effects of Gadolinium thus providing inherent
rCBV correction and tracer kinetics. Results show
elevated rCBV in astrocytoma relative to pineal
germinoma. The specificity of 18FFE Cho provides clear
outlining of tumourous regions for kinetic evaluation.
PET and MRI images are also inherently coregistered
using this technique.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
